TISIDB

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endomembrane system; Single-pass membrane protein. Mitochondrion membrane Single-pass membrane protein Note=Around the nuclear envelope, and in cytoplasmic membranes.
Domain	PF12201 Bcl2-interacting killer
Function	Accelerates programmed cell death. Association to the apoptosis repressors Bcl-X(L), BHRF1, Bcl-2 or its adenovirus homolog E1B 19k protein suppresses this death-promoting activity. Does not interact with BAX.

> Gene Ontology [ TOP ]
Biological Process	GO:0001836 release of cytochrome c from mitochondria GO:0007283 spermatogenesis GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0008637 apoptotic mitochondrial changes GO:0010821 regulation of mitochondrion organization GO:0010822 positive regulation of mitochondrion organization GO:0031334 positive regulation of protein complex assembly GO:0032459 regulation of protein oligomerization GO:0032461 positive regulation of protein oligomerization GO:0032462 regulation of protein homooligomerization GO:0032464 positive regulation of protein homooligomerization GO:0043254 regulation of protein complex assembly GO:0044089 positive regulation of cellular component biogenesis GO:0045137 development of primary sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046661 male sex differentiation GO:0048232 male gamete generation GO:0048608 reproductive structure development GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0061458 reproductive system development GO:0090199 regulation of release of cytochrome c from mitochondria GO:0090200 positive regulation of release of cytochrome c from mitochondria GO:2001233 regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway
Molecular Function	GO:0046982 protein heterodimerization activity GO:0051400 BH domain binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between BIK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between BIK and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
21282355	Lung Carcinoma	Promote immunity (T cell function)	Here, we found this cancer-targeted gene therapy, SV-BikDD, composed of the survivin promoter in the VP16-GAL4-WPRE integrated systemic amplifier system to drive the apoptotic gene BikDD, not only caused cytotoxic effects in cancer cells but also elicited a cancer-specific cytotoxic T lymphocyte response to synergistically increase the therapeutic effect and further develop an effective systemic antitumoral immunity against rechallenges of tumorigenic dose of parental tumor cells inoculated at distant sites in immunocompetent mice.

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of BIK in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of BIK in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.441	0.42
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.866	0.368
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.129	0.875
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.244	0.755
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.143	0.91
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.73	0.613
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.937	0.189
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.993	0.35
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.915	0.419
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.391	0.409
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.237	0.171

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of BIK in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BIK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BIK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BIK. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BIK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of BIK expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between BIK and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	BIK
Name	BCL2-interacting killer (apoptosis-inducing)
Aliases	NBK; BIP1; BP4; apoptosis inducer NBK; apoptosis-inducing NBK; Bcl-2-interacting killer
Chromosomal Location	22q13.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting BIK collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse BIK